Know Cancer

or
forgot password

Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762


N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762


Approximately 75% of all invasive breast cancers are hormone sensitive [estrogen-receptor
positive (ER+) or progesterone-receptor positive (PR+)] and patients with such cancers are
candidates for endocrine therapy. Endocrine therapy is a central component of the treatment
of hormone-sensitive breast cancer in the adjuvant and, increasingly, neoadjuvant settings.
Knowledge of hormone receptor expression is essential for selection of appropriate therapy.
Measurement of hormone-receptor expression [estrogen receptor (ER) or progesterone receptor
(PR)] using in vitro assays of the tumor tissue at the time of primary diagnosis is standard
of clinical care. However, the presence of these hormone receptors predicts for clinical
benefit in only 30-50% of women with advanced disease receiving first-line endocrine therapy
and 15-30% receiving second-line therapy (1-3). Thus, the presence of a hormone receptor
does not indicate that the receptor is functional and essential to the growth of the cancer
cell, nor does it imply that interference with receptor function will result in tumor cell
kill. There are several shortcomings of the in vitro assays and neither quantitative nor
qualitative receptor assays performed on samples of tumor tissue completely predict the
response to antiestrogen therapy in breast cancers. In addition, none of the current
clinical tools (serologies, prognostic factors, or radiologic studies) can accurately
predict for clinical benefit from endocrine therapy. Accordingly, better methods for
predicting clinical response to antiestrogen therapy need to be developed.


Inclusion Criteria:



1. Patients must have agreed and signed consent to participate in NCI protocol 8762 and
be scheduled to receive the first dose of MK-2206 in a minimum of 48 hours and a
maximum of 30 days after the FES-PET/CT imaging.

Note: Patients need to be on the endocrine agent for at least 1 week prior to the
FES-PET/CT imaging.

2. Patients must have measurable disease (defined by RECIST criteria) or the presence of
bone lesions if there is no measurable lesion.

3. Patient must be ≥ 18 years of age.

4. Patient must be able to tolerate and have no contraindication to FES-PET/CT imaging.

5. Patient must be able and willing to give informed consent.

Exclusion Criteria:

1. Patient must have no other active cancer at the time of study entry.

2. The research FES-PET/CT scan could not be scheduled more than 48 hours before
starting therapy with MK-2206.

3. Patient cannot have received treatment for any other malignancy, with the exception
of non-melanoma skin cancer, in the past 5 years.

4. Patients scheduled to receive chemotherapy as the primary source of treatment

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

FES baseline tumor SUV measurement

Outcome Time Frame:

Up to 36 months

Safety Issue:

No

Principal Investigator

Farrokh Dehdashti, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington Univesity in St. Louis

Authority:

United States: Food and Drug Administration

Study ID:

Dehdashti FES NCI#9167

NCT ID:

NCT01714128

Start Date:

June 2013

Completion Date:

December 2015

Related Keywords:

  • Breast Cancer
  • NCI protocol #8762
  • Estrogen receptor positive breast cancer
  • recurrent breast cancer
  • stage IV breast cancer
  • Breast Neoplasms

Name

Location

Mallinckrodt Institute of RadiologySaint Louis, Missouri  63110